PTPRC and Miyoshi myopathy: To address these limitations, we utilized the High-Definition Single Cell Assay (HDSCA) workflow as a non-enrichment liquid biopsy tool to analyze PB samples from 68 patients across the MM disease spectrum, leveraging an immunofluorescence assay targeting CD138, BCMA, and CD45 to identify a diverse population of tumor-associated circulating PCs and differentiate disease states.